17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7138396B2 · kind B2 · utility
0Cited by
18References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2005 |
| Grant date | Nov 21, 2006 |
| Priority date | — |
| Expiry date | Oct 24, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
There are disclosed compounds of the formula (I):prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.